AbstractMultidrug resistance (MDR), which is the main obstacle to cancer chemotherapy, is mainly due to overexpression of ATP-binding cassette (ABC) transporters, especially ABCB1 (P-glycoprotein), ABCC1 (MRP1), and ABCG2 (BCRP). A novel idea to overcome MDR is that of collateral sensitivity, i.e., finding a treatment to which cells overexpressing ABC transporters are more sensitive than cells that do not overexpress them. In this study we demonstrate for the first time that MDCKII-BCRP cells, overexpressing ABCG2, are more vulnerable to exogenous oxidative stress induced by several oxidants, viz. paraquat, menadione, hydrogen peroxide, tert-butylperoxide, and 2,2-azobis(2-methylpropionamidine) dihydrochloride. MDCKII-BCRP cells have signif...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...
AbstractMultidrug resistance (MDR), which is the main obstacle to cancer chemotherapy, is mainly due...
Multidrug resistance (MDR) in cancer is a phenomenon that impairs efficient treatment that has no...
Multidrug resistance or MDR in cancer has been recognized as a major obstacle limiting efficient tre...
AbstractThe human ABCG2 (ABCP/MXR/BCRP) protein is a recently recognized ABC half-transporter, which...
ABCB1, ABCC1 and ABCG2 are the 3 human ABC transporters mainly involved in chemoresistance of some c...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance protein, BCRP...
AbstractRecent studies have characterized the ABC half-transporter associated with mitoxantrone resi...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...
AbstractMultidrug resistance (MDR), which is the main obstacle to cancer chemotherapy, is mainly due...
Multidrug resistance (MDR) in cancer is a phenomenon that impairs efficient treatment that has no...
Multidrug resistance or MDR in cancer has been recognized as a major obstacle limiting efficient tre...
AbstractThe human ABCG2 (ABCP/MXR/BCRP) protein is a recently recognized ABC half-transporter, which...
ABCB1, ABCC1 and ABCG2 are the 3 human ABC transporters mainly involved in chemoresistance of some c...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance protein, BCRP...
AbstractRecent studies have characterized the ABC half-transporter associated with mitoxantrone resi...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple chemotherapeutic d...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...
Multidrug resistant (MDR) cancers often become resistant to pharmacologically and structurally diver...